Oncology Expert Insights

Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.

Dr. Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.

Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.

Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.

Dr Hua talks about the unmet need in neuroendocrine tumors (NETs), explains the difficulty of detecting NETs, and highlights his study findings evaluating anti-CDH17 CAR T cells in this disease.

Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.

Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.

Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.

Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendations for fixing peer review, and explaining how this affects cancer research.

Dr Jabbour discusses updates from the 2021 ASH Annual Meeting and Exposition in chronic myeloid leukemia, including findings from the phase 3 ASCEMBL trial evaluating asciminib vs bosutinib and data with ponatinib from a post-hoc analysis of the phase 2 OPTIC trial.

Dr Bardia discusses data from DESTINY-Breast03, HER2CLIMB, and NALA, important findings that were presented at the 2021 San Antonio Breast Cancer Symposium for patients who have HER2-positive metastatic breast cancer.

Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.

Dr Tripathy explains the rationale for the TBCRC049 trial, the challenges of investigating a disease that appears in less than 5% of patients with breast cancer, and potential avenues for future investigations.

Drs Lyle and Patel review some of the challenges associated with the diagnosis and management of myelodysplastic syndromes, the current treatment landscape, and the role of next-generation sequencing and optimal testing practices in the field.

Dr Ross shares his advice to health care professionals regarding the detection and treatment of patients with colon cancer, unmet needs for this patient population, the role of minimally invasive surgery, and the need to address and overcome health disparities that affect this population.

Dr Hurvitz sheds light on shifts in practice patterns in HER2-positive breast cancer in light of data that emerged in 2021, remaining questions regarding treatment sequencing, the importance of updates to the National Comprehensive Cancer Network guidelines in metastatic HER2-positive breast cancer, and future directions to keep an eye on in 2022.

Dr Jain discusses the current utility of frontline maintenance therapy in advanced ovarian cancer, dosing strategies with PARP inhibitors, and management strategies for common adverse effects associated with these therapies.

Dr Milhem discusses the unique mechanism of action and delivery method of RP1, which is being evaluated in the IGNYTE trial for patients with solid tumors, as well as the parallel studies ARTACUS and CERPASS, which are further exploring the agent.

Dr Ramchandren discusses current treatment options for patients with Waldenström macroglobulinemia who have limited response to other therapies, the rationale for the expansion cohort of the phase 2 CLOVER-WaM trial evaluating CLR 131 in these patients, and other anticipated research trends in this paradigm.

Dr Wang discusses the clinical experience with ibrutinib in mantle cell lymphoma, its present role in the management of MCL, and ongoing research that may affect its use as a single agent.

Dr Basu discusses the “shadow curve” that could result from disruptions in cancer care during the COVID-19 pandemic and innovative strategies that Cancer Treatment Centers of America are taking to avoid this.

Dr Meyer discusses the rarity of cardiac angiosarcoma, optimizing detection strategies, surgical interventions, and chemotherapy for this patient population, and why immunotherapy has the potential to transform care for patients.

Dr Gilbert discusses her new role as associate director for research, education, and professional development at Vanderbilt University Medical Center and shares some of her short- and long-term goals in this position.

Dr Bardia discusses the role of sacituzumab govitecan in the treatment of patients with metastatic triple-negative breast cancer, the influence of the National Comprehensive Cancer Network guidelines on treatment recommendations and sequencing in the second-line setting, and ongoing research with the agent in the neoadjuvant setting.

Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential for retreatment following toxicity resolution.

Dr Phillips discusses the utility of ibrutinib, acalabrutinib, and zanubrutinib in mantle cell lymphoma, the impact of long-term follow-up data with ibrutinib, and findings from the phase 3 SYMPATICO trial that could shake up the treatment paradigm.